Chi Dennis S, Abu-Rustum Nadeem R, Sonoda Yukio, Im HyunSoon Beatrice, Jhamb Namita, D'Angelica Michael, Rim Mina, Dupont Jakob, Barakat Richard R
Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, MRI-1026, New York, NY 10021, USA.
Gynecol Oncol. 2006 May;101(2):224-7. doi: 10.1016/j.ygyno.2005.10.037. Epub 2005 Dec 9.
Prolonged survival in patients with recurrent ovarian cancer isolated to the spleen has been demonstrated after successful splenectomy. The purpose of this study was to report the outcomes of a series of patients who underwent splenectomy for persistent or recurrent ovarian cancer via laparoscopy or hand-assisted laparoscopy.
We reviewed the charts of all patients who underwent laparoscopic or hand-assisted laparoscopic splenectomy for presumed persistent or recurrent ovarian cancer. Demographic, clinical, pathologic, and follow-up information was abstracted.
Six patients underwent laparoscopy or hand-assisted laparoscopy for presumed ovarian cancer involving the spleen. In 5 of the 6 cases, laparoscopic or hand-assisted laparoscopic splenectomy was successfully performed. For the 5 laparoscopic cases, operative times varied from 155 to 315 min, and estimated blood loss ranged from 50 to 300 ml. There were no perioperative mortalities or significant complications. Hospitalization lasted from 3 to 5 days. Four patients are alive with no evidence of disease at 2-84 months from the splenectomy, while 1 patient died of disease 20 months after the procedure. The sixth patient underwent initial hand-assisted laparoscopy, and the case was immediately converted to laparotomy for resection of peritoneal carcinomatosis.
Laparoscopic and hand-assisted laparoscopic splenectomies are safe and feasible in the management of patients with presumed persistent or recurrent ovarian cancer. Larger studies are necessary and eagerly awaited to help determine the long-term risks and benefits as well as the most appropriate candidates and selection criteria.
已证实,对孤立转移至脾脏的复发性卵巢癌患者成功实施脾切除术后可延长生存期。本研究的目的是报告一系列经腹腔镜或手辅助腹腔镜对持续性或复发性卵巢癌实施脾切除术患者的治疗结果。
我们回顾了所有因疑似持续性或复发性卵巢癌而接受腹腔镜或手辅助腹腔镜脾切除术患者的病历。提取了人口统计学、临床、病理及随访信息。
6例患者因疑似卵巢癌累及脾脏而接受了腹腔镜或手辅助腹腔镜手术。6例中有5例成功实施了腹腔镜或手辅助腹腔镜脾切除术。对于5例腹腔镜手术病例,手术时间为155至315分钟,估计失血量为50至300毫升。无围手术期死亡或严重并发症。住院时间为3至5天。4例患者在脾切除术后2至84个月存活且无疾病证据,而1例患者在术后20个月死于疾病。第6例患者最初接受了手辅助腹腔镜手术,该病例立即转为开腹手术以切除腹膜癌。
腹腔镜和手辅助腹腔镜脾切除术对于疑似持续性或复发性卵巢癌患者的治疗是安全可行的。需要并迫切期待开展更大规模的研究,以帮助确定长期风险和益处以及最合适的候选患者和选择标准。